![\"\"](\"https:\/\/static.stocktitan.net\/img\/icons\/Google_News_icon.svg\"){kind=icon}
<\/p>\n
\n
\n
<\/p>\n
Key Terms<\/p>\n
\n
\n clinical trials
\n
\n medical
\n
\n
<\/p>\n
Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company\u2019s future revenue, valuation and risk profile\u2014think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.<\/p>\n
<\/p>\n
\n
\n real-world evidence
\n
\n medical
\n
\n
<\/p>\n
Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.<\/p>\n
<\/p>\n
\n
\n electronic health record
\n
\n technical
\n
\n
<\/p>\n
A digital version of a patient\u2019s medical chart that collects health information \u2014 diagnoses, medications, lab results, imaging and doctors\u2019 notes \u2014 in one place so authorized clinicians can view and update it. For investors, electronic health records matter because they drive revenue and costs for companies that build, sell or rely on them, influence how quickly care is delivered, and create opportunities (and risks) tied to data access, software updates, regulation and patient privacy. Think of it as an online file cabinet for health that affects how the healthcare system runs and spends money.<\/p>\n
<\/p>\n
\n
\n ai
\n
\n technical
\n
\n
<\/p>\n
Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.<\/p>\n
<\/p>\n
\n
\n
\n
\n
\n
<\/p>\n
<\/p>\n
\n
\n See more from StockTitan in Google Search and AI answers.
\n Adds StockTitan as a preferred source \u00b7 opens Google
\n <\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 07\/17\/2026 – 08:30 AM
\n
\n
<\/p>\n
\nHenry Ford Health selected as one of only four U.S. academic health systems in Bayer\u2019s strategic research network<\/p>\n
DETROIT–(BUSINESS WIRE)–
\nBayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer\u2019s global drug development expertise with Henry Ford Health\u2019s comprehensive clinical research program and its deep connection to the communities it serves.<\/p>\n
\n\u201cClinical trials are often the first opportunity patients have to access cutting-edge treatments,\u201d said Dr. David Lanfear, Chief Scientific Officer for Henry Ford Health. \u201cThrough this collaboration, we aim to make clinical research more accessible, reduce barriers to participation, accelerate the development of new treatments and ensure that more patients have the opportunity to benefit from medical innovation.\u201d<\/p>\n
\nInitial efforts will focus on several key areas that align with Bayer\u2019s growing pipeline and product offerings:<\/p>\n
Cardiovascular and renal disease, including thrombosis, heart failure, stroke, and chronic kidney disease<\/p>\n
Oncology, including advanced cancers and targeted therapies<\/p>\n
Women\u2019s health, including treatments for menopausal symptoms and gynecologic conditions<\/p>\n
\nTogether, the organizations will collaboratively work across the full clinical trial process, using data and technology to design smarter trials. Patients will be able to access novel treatments sooner by reducing barriers to participation.<\/p>\n
\n\u201cBayer is consistently exploring new avenues that can help more patients with diseases or health conditions that impact millions of people across the world,\u201d said Christoph Koenen, Head, Clinical Development & Operations for Bayer. \u201cWe share this commitment to patients and advancing drug discovery with likeminded institutions like Henry Ford Health that can help reduce barriers to accessing investigational or potential new treatments right in the very communities where patients are already receiving their care.\u201d<\/p>\n
\nThe partnership will add more areas of medicinal research as time goes on. Beyond clinical trials, the organizations plan to work together in areas such as:<\/p>\n
Using AI, analytics, and electronic health record data to improve trial design and patient identification<\/p>\n
Generating real-world evidence to better understand how treatments perform<\/p>\n
Supporting training and innovation in healthcare data science<\/p>\n
\nThe partnership reflects a shared commitment to advancing clinical research in ways that are faster, more inclusive, and more accessible for patients.<\/p>\n
\nHenry Ford Health is one of only four academic health systems in the U.S. selected to work with Bayer in this strategic research model, reflecting its clinical expertise, integrated care network, diverse patient population and strong track record in clinical research. In July, Bayer announced its first strategic alliance with the University of Colorado Anschutz<\/a>, UCHealth<\/a> and Children\u2019s Hospital Colorado<\/a> to advance drug development and clinical trials.<\/a><\/p>\n \n\u201cThis partnership builds on Henry Ford Health\u2019s longstanding leadership in clinical research and creates new opportunities to bring innovative studies to our patients,\u201d Lanfear said. \u201cBy combining our expertise with Bayer\u2019s global research capabilities, we can help advance treatments in areas that matter most while ensuring research reflects the needs of the diverse communities we serve.\u201d<\/p>\n \nAbout Bayer \nAbout Henry Ford Health View source version on businesswire.com: https:\/\/www.businesswire.com\/news\/home\/20260716388316\/en\/<\/a><\/p>\n \nElaine Colon
\n
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, \u201cHealth for all, Hunger for none,\u201d the company\u2019s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros.<\/p>\n
\n
Serving communities across Michigan and beyond, Henry Ford Health is a premier healthcare organization dedicated to helping people live their best lives. More than 50,000 team members provide care and service at hundreds of locations, offering everything from primary, preventive and urgent care to specialized treatment, health coverage, pharmacy and vision services, home health, and virtual care. Henry Ford Health is also a leading academic health system advancing the future of medicine through innovation, clinical trials, translational research, and the education of healthcare professionals. Henry Ford\u2019s clinical research is part of Henry Ford Health + Michigan State University Health Sciences, accelerating discovery across biomedical and population health research while training the next generation of healthcare providers and scientists. Together, this work is focused on breakthroughs in prevention, early detection, diagnosis, treatment, and health and wellness.<\/p>\n<\/p>\n
\n
elaine.colon@bayer.com
\n<\/a><\/p>\n